Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene represents a **pseudogene** similar to a region of the AAAS gene, associated with clinical features such as achalasia, adrenocortical insufficiency, and alacrimia (Allgrove syndrome)[2]. Pseudogenes are typically nonfunctional DNA elements derived from ancestral protein-coding genes that have accumulated mutations and lost their coding potential[3][4]. While some pseudogenes can exert regulatory roles at the RNA level—such as acting as microRNA sponges, producing short interfering RNAs, or influencing transcription—most remain poorly characterized for functional impact. For ENSG00000219549, no protein is produced, and no experimental data supports direct involvement in disease, signaling pathways, or drug interactions[2][3][4]. ENSG00000219549 is a nonfunctional pseudogene defined by sequence similarity to a segment of the AAAS gene; it does not represent a canonical molecular target from the standpoint of therapeutics or molecular pharmacology, and available information is descriptive rather than functional[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to part of Achalsia, Adrenocortical Insufficiency, Alacrimia (Allgrove, Triple-A) AAAS.